Cytomegalovirus Immune Globulin
Cytomegalovirus Immune Globulin is a specialized antibody preparation derived from human plasma that provides passive immunity against CMV. It is primarily used to prevent CMV disease in immunocompromised patients, particularly those who have received organ or bone marrow transplants. This medication helps reduce the risk of serious CMV-related complications in high-risk individuals who lack natural immunity to the virus.
Cytomegalovirus Immune Globulin is a blood product used to prevent CMV infection in immunocompromised transplant patients.
Key facts at a glance
- ATC
- J06BB09
- RxNorm
- 22178
- Generic
- Cytomegalovirus Immune Globulin
- Class
- atc-j06
- Brands
- Cytogam
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
11 groupspregnancy
first trimesteravoid if possible
use only if clearly needed and benefits outweigh risks; consider alternative therapies first
regular fetal monitoring and ultrasound assessments
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
use only if clearly needed for CMV prophylaxis or treatment
regular fetal monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimesterstandard dosing may be used
use only if benefits outweigh risks; consider timing of administration
regular fetal monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingno adjustment needed
generally considered compatible with breastfeeding; immune globulins not significantly absorbed from GI tract
no specific monitoring required
pediatric_age
infantsweight-based dosing required
use in pediatric patients is established for transplant recipients; dosing based on body weight
monitor vital signs during infusion; assess renal function
Use with caution and monitor for adverse effects.
pediatric_age
childrenweight-based dosing required
safe and effective for CMV prophylaxis in children receiving organ transplants
monitor for infusion-related reactions; renal function monitoring
geriatric
elderlystandard dosing with close monitoring
use with caution due to potential age-related renal and cardiac changes
monitor renal function, vital signs, and fluid status closely
Use with caution and monitor for adverse effects.
renal_impairment
mildstandard dosing
use standard dosing; monitor renal function
baseline and periodic renal function monitoring
renal_impairment
moderate to severeuse with caution
use with caution; some formulations contain sucrose which may increase renal risk
close renal function monitoring; ensure adequate hydration
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderatestandard dosing
no specific dose adjustment required; immune globulins do not undergo hepatic metabolism
standard monitoring
hepatic_impairment
severeuse with caution
limited data in severe hepatic impairment; use only if benefits outweigh risks
monitor liver function tests and clinical status
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
Initial FDA approval for CMV prophylaxis in transplant patients
Drug class
Hyperimmune globulin for cytomegalovirus
Primary indication
Used in solid organ and bone marrow transplant recipients
Mechanism of action
Provides passive immunity against cytomegalovirus
Prevention of cytomegalovirus (CMV) disease in solid organ transplant recipients and bone marrow transplant patients who are at high risk for CMV infection or reactivation.
Provides passive immunization by delivering CMV-specific antibodies that help neutralize the virus and reduce the severity of CMV infection until the patient's own immune system can respond effectively.
Administered intravenously by healthcare professionals. May cause infusion-related reactions. Regular monitoring for signs of CMV disease is still necessary as this provides passive immunity rather than active immunity. Use with caution in patients with immunoglobulin A deficiency or history of severe allergic reactions to blood products.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy